Alpha Fusion Accelerates Astatine-based Drug Discovery with Series B Funding

OSAKA, Japan, Oct. 9, 2024 /PRNewswire/ — Alpha Fusion, Inc. (CEO: Sunao Fujioka, headquartered in Kita-ku, Osaka), has raised a total of Â¥1.02 billion through a Series B funding round. The round was led by SBI Investment Co., Ltd. and OSAKA University Venture Capital, with participation…